Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 6 от 222

Набира участници Фаза 1

Phase I Study of HXN6005 in Adult Healthy Participants

Healthy Volunteers (HV)

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

Начало: 27.04.2026 Край: 13.03.2027 Възраст: 18–55 г. Лечение

Australia Helixon Biotechnology (Suzhou) Co., Ltd NCT07449741

Набира участници

Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults

Healthy Volunteers Speech

This study examines whether individual differences in how speakers respond to hearing versus physical sensation during speech can predict who benefits most from visual feedback during a speech task. Healthy adults will complete a series of tasks in which auditory feedback is altered in real time through headphones, with and without an added visual display of the speech signal. A computational model will be used to estimate how strongly each participant relies on hearing versus physical sensation when monitoring speech. The study will then test whether this individual profile predicts how much the visual display improves each participant's ability to respond to the altered feedback.

Начало: 24.04.2026 Край: 30.11.2026 Възраст: 18–45 г.

United States New York University NCT07530900

Набира участници

Computer Guided Microwave Liver Ablation

Hepatocellular Carcinoma (HCC)

The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the target tumor has, and has not been treated at any point during the procedure. The main questions it aims to answer are: 1) Does the use of the computer guidance software reduce the number of times a tumor is incompletely treated. 2) Does the use of the computer guidance software reduce the rate of local tumor recurrence at 2 year follow-up? 3) Was there an increase or a decrease in medical problems for participants after a procedure where the guidance software was used? Researchers will compare liver tumor treatment using the computer guidance software with an historic control to see if the addition of the guidance software improved the outcomes after an ablation. Participants will: Undergo CT-guided microwave ablation treatment of a liver tumor using computer-assisted simulation. Visit the clinic at one month and then every 3 months for blood tests and a contrast-enhanced CT or MRI imaging study (as per standard of care)

Начало: 24.04.2026 Край: 28.02.2030 Възраст: 18–90 г.

United States NE Scientific INC NCT07226869

Набира участници

Effect of Lateral Versus Supine Positions on Postoperative Hypoxemia

Postoperative Hypoxemia

Using prospective real-world data, this study aims to determine whether the lateral decubitus position reduces the incidence of post-procedure hypoxemia in patients undergoing painless gastroscopy/colonoscopy, thereby providing a simple, non-invasive, and low-cost optimization strategy for clinical practice.

Начало: 23.04.2026 Край: 30.06.2026 Възраст: от 18 г.

China General Hospital of Ningxia Medical University NCT07545642

Набира участници Фаза 2

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Acute Lymphoblastic Leukemia Obesity

This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \

Начало: 23.04.2026 Край: 01.11.2028 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT07228741

Набира участници Фаза 1

A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

Type I diabetes

Trial status: Authorised

Начало: 23.04.2026 Възраст: 18–64 г.

Germany Novo Nordisk A/S 2025-523978-16-00

Набира участници Фаза 2

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial

deep vein thrombosis

Trial status: Authorised Proportion of patients with PTS (Villalta score ≥5) at 6 months, Proportion of patients according to the following PTS severity categories based on Villalta score category: mild (Villalta Score 5-9), moderate (Villalta score 10-14), severe (Villalta score ≥15 or presence of ulcer) at 6 and 12 months, Mean Villalta score and mean change from baseline (based on continuous Villalta score) at 6 and 12 months to estimate the severity of PTS, Incidence rate of recurrent venous thromboembolism (VTE) during follow-up (up to 12 months), Incidence rate of arterial thromboembolism (ATE) during follow-up (up to 12 months), Incidence rate of composite of adverse vascular events (comprising PTS, recurrent VTE, ATE) during follow-up (up to 12 months), Incidence rate of major bleeding (as per International Society of Thrombosis and Haemostasis (ISTH) definition) during follow-up (up to 12 months), Incidence rate of clinically relevant non-major bleeding (as per ISTH definition) during follow-up (up to 12 months), All-cause mortality rate, Mean changes in patient-reported outcome measures (PROMs) from baseline to 6 and 12 months as assessed by functional scales (Patient reported Villalta-scale - PRV, Post-venous thromboembolism functional status - PVFS), and generic health-related and disease specific QOL questionnaires (EuroQoL-EQ-5D-5L, VEINES QOL/Sym, PEmb-QoL), Safety endpoints: 1.Number and incidence rate of gastrointestinal adverse events that result in study drug discontinuation 2.Number and incidence rate of muscle pain episodes that results in study drug discontinuation 3.Number and incidence rate of infections episodes leading to hospitalization. Other: renal insufficiency; neutropenia and/or neuropathy leading to study drug discontinuatio PTS (Villalta score ≥5) at 12 months

Начало: 23.04.2026 Възраст: от 18 г.

Italy Universita' Degli Studi G. D'Annunzio Di Chieti 2025-521836-12-00

Набира участници Фаза 2

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

Kidney disease

Trial status: Authorised Time to remission (either complete or partial), Time to complete remission, Time to disease relapse, Change in Glucocorticoid Toxicity Index (GTI) from baseline to day 60, week 26 and 52, Change in urinary protein-to-creatinine ratio/albumin-to-creatinine ratio from baseline to week 26 and 52, Change in serum albumin from baseline to week 26 and 52, Kidney function as assessed by changes in 2021 race-free CKD-EPI estimated glomerular filtration rate (eGFR) from baseline to week 26 and 52, Patient-reported health–related QoL assessed by EuroQol 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L), Predictors of disease relapse (independent of treatment assignment): Demographics, clinical characteristics, biological variables and histopathological characteristics, Safety endpoint: Serious adverse events (assessed by CTCAE v5; defined as grade ≥3) during the study period of 52 weeks, Safety endpoint: Adverse events of special interest (AESI) and infection events during the study period of 52 weeks, Safety endpoint: The proportion of patients with overall and mild hypogammaglobulinemia (

Начало: 23.04.2026 Възраст: от 18 г.

France, Germany Medizinische Universitaet Innsbruck 2025-520641-69-00

Набира участници Фаза 2

A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.

Type 2 Diabetes

Trial status: Authorised 1. Change in transgene secretion and glycemic parameters., 2. Anti-AAV9 antibody titers, anti-GLP-1 antibody titers and enzyme-linked immunosorbent spot for AAV9 and GLP-1., 3. Digital polymerase chain reaction for AAV9 in samples., 4. Change from Baseline parameters using continuous glucose monitoring. Incidence, severity, dose-relationship of Adverse Events and changes in laboratory evaluations.

Начало: 23.04.2026 Възраст: от 18 г.

Netherlands Fractyl Health Inc. 2025-524438-24-00

Набира участници Фаза 4

A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).

Respiratory Tract Infections

Trial status: Authorised - % of pts free of RTI during the overall study period - Mean duration in days per RTI during the overall study period (OST) – No. of days with RTI during the OST – No. of days of antibiotics use during the OST - Total no. of workdays lost by parents due to their child’s RTI during the OST – No. of physician consultations due to RTI or related complications – No. of antibiotic treatments (courses) for a respiratory event during the OST – No. of pts with (serious) AE and (serious) ADR Rate of Respiratory Tract Infections (RTIs): the number of RTIs experienced by a subject throughout the study (3 month-treatment period and 4 month-follow-up) will be assessed.

Начало: 23.04.2026

Poland Lallemand Pharma Europe filial af Lallemand Pharma AG S 2025-524212-11-00

Набира участници Фаза 1

Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY

Medulloblastoma (recurrent or progressive)

Trial status: Authorised 1. PK parameters of RVU120 as a single agent and in combination with everolimus, including Cmax, AUCτ, tmax, AUC0 - ∞, t1/2 2. Ctrough of everolimus in combination with RVU120 3. Overall response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS) in accordance with RAPNO guidelines, where applicable, stratified by molecular subgroup (G3 vs. G4) and MYC or MYCN expression in combination therapy of RVU120 and everolimus 1. Frequency and nature of AEs, SAEs and DLTs according to CTCAE v5.0 in RVU120 monotherapy and combination therapy with everolimus 2. MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus

Начало: 23.04.2026

Poland Instytut Pomnik Centrum Zdrowia Dziecka 2025-524031-39-00

Набира участници Фаза 3

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

Diabetes Mellitus Cardiovascular disease Overweight (BMI ≥27 kg/m²) Obesity (BMI≥30kg/m2)

Trial status: Authorised Changes between groups at different time points (T1, T2 and T3) in: • Markers of thrombus formation (T-TAS AUC, P-selectin, aGPIIbIIIa, PDMP) • Inflammatory markers (IL-1, IL-6); • Oxidative stress markers (H₂O₂, sNOX2-dp, HBA); • Endothelial function markers (NO, endothelin-1); • Autophagy markers (p62, LC3, ATG5). Change in platelet reactivity assessed by light transmission aggregometry [LTA] following ADP (2 and 5 μmol/L) and collagen (2 μg/mL) stimuli between groups at T3;

Начало: 23.04.2026 Възраст: от 18 г.

Italy Casa Di Cura Accreditata Istituto Chirurgico Ortopedico 2025-522486-29-01

Набира участници

Strategic Comparison Of Ischemia-based Versus Plaque Burden and vulnErability-based Revascularization in High-Risk Coronary Artery Disease Patients

Coronary Artery Disease

1. Study Purpose This study aims to compare clinical outcomes between two revascularization strategies in patients with high-risk coronary artery disease and 50-90% angiographic stenosis: a plaque burden and vulnerability-based revascularization strategy guided by intravascular imaging versus an ischemia-based revascularization strategy guided by physiologic assessment. 2. Background Percutaneous coronary intervention (PCI), in conjunction with optimal medical therapy, is one of the main therapeutic strategies for improving outcomes in patients with CAD. To enhance the results of PCI, various diagnostic and adjunctive techniques have been developed-most notably, invasive physiologic assessment and intravascular imaging (IVI). Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are recognized as the most accurate methods to determine vessel-level myocardial ischemia, and current guidelines recommend PCI based on these physiological measurements. Recently, angiography-derived FFR has also been developed, allowing ischemia assessment without pressure wire measurement, and has been endorsed as a useful tool for guiding PCI decisions. Intravascular imaging, on the other hand, provides detailed anatomical insights into atherosclerotic plaque morphology and plays a critical role in achieving procedural optimization. Current guidelines recommend the use of IVI, particularly in the treatment of complex lesions. While most previous IVI studies have focused on procedural optimization, more recent investigations have begun to explore the use of IVI for PCI decision-making itself. Emerging data suggest that revascularization decisions based on quantitative and qualitative plaque assessment using IVI are non-inferior to those based on invasive physiologic testing. Moreover, IVI enables the identification of vulnerable plaques, and studies indicate that intervening on such lesions may improve outcomes. At present, a physiology-guided decision-making strategy combined with IVI-guided optimization is considered the best evidence-based approach according to guidelines. However, recent data showing the potential advantages of IVI-guided decision-making and IVI-guided optimization-particularly in high-risk, complex patients and in those with vulnerable plaque morphology-suggest that IVI-based strategies may offer greater clinical benefit in such populations. Despite this, a comprehensive strategy that integrates both quantitative (plaque burden) and qualitative (vulnerability) aspects of plaque evaluation via IVI has yet to be clearly established. Therefore, this study seeks to propose IVI-based quantitative and qualitative criteria for high-risk CAD patients and to compare outcomes between a plaque burden and vulnerability-based revascularization strategy and the conventional ischemia-based revascularization strategy. For all patients undergoing PCI, IVI-guided optimization will be performed to ensure the highest possible procedural quality in both groups. 3. Study Procedures Patients undergoing coronary angiography for suspected or known CAD will be screened for eligibility. After providing a detailed explanation of the study, written informed consent will be obtained from those deemed appropriate for participation. Following coronary angiography, patients with significant coronary stenosis who meet all inclusion and no exclusion criteria will be enrolled in the study. Eligible participants will then be randomized in a 1:1 ratio to either the plaque burden and vulnerability-based revascularization group or the ischemia-based revascularization group. Stratified randomization will be performed according to participating center and presence or absence of acute coronary syndrome (ACS) to ensure balance between the groups.

Начало: 23.04.2026 Край: 24.09.2033 Възраст: от 19 г.

South Korea Bon-Kwon Koo NCT07324720

Набира участници

Rutgers University Study of the Genetics of Kidney Disease

Kidney Disease Kidney Disease, Chronic Kidney Disease, End-Stage Kidney Diseases +2

The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.

Начало: 23.04.2026 Край: 31.10.2028 Възраст: от 18 г.

United States Rutgers, The State University of New Jersey NCT07217535

Набира участници Фаза 4

Aminoglycosides in Early Sepsis

Sepsis

Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance. In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.

Начало: 23.04.2026 Край: 01.05.2033 Възраст: от 18 г.

Norway University Hospital, Akershus NCT06712641

Набира участници

Comparative Study Between Cannulated Screws and K-wires in the Fixation of Distal Radius Fractures

Distal Radius Fractures

This comparative study aims to evaluate the clinical and radiological outcomes of cannulated screw fixation versus K-wire fixation in the treatment of distal radius fractures. Adult patients with distal radius fractures will be allocated to either cannulated screw fixation or K-wire fixation. The primary outcome measure will be functional outcome assessed using the DASH score, with secondary outcomes including radiographic parameters and complication rates.

Начало: 22.04.2026 Край: 23.01.2027 Възраст: 18–60 г.

Egypt Sohag University NCT07523386

Набира участници Фаза 1

Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms

Malignant B-cell neoplasms

Trial status: Authorised

Начало: 22.04.2026 Възраст: от 18 г.

Spain Fundacion Para La Investigacion Biomédica Del Hospital 2025-524814-27-00

Набира участници Фаза 4

Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

No medical condition.

Trial status: Authorised

Начало: 22.04.2026 Възраст: 18–64 г.

Portugal Institut De Recherches Internationales Servier IRIS 2026-526040-13-00

Набира участници Фаза 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Trial status: Authorised 1. HbA1c < 7.0% 2. HbA1c ≤ 6.5% 3. Change of TIR on CGM from baseline 4. Change in FPG from baseline 5. Change in body weight from baseline 6. Percent change in body weight from baseline 7. Body weight loss ≥ 5% 8. Body weight loss ≥ 10% 8. Body weight loss ≥ 10%, 9. Change in SBP and DBP from baseline 10. Number of level 2 hypoglycemic episodes or severe hypoglycemic episodes 11. TEAE & AESI; 12. Population PK parameters Change in HbA1c from baseline

Начало: 22.04.2026 Възраст: от 18 г.

Poland Corxel Pharmaceuticals Inc. 2025-524514-28-00

Набира участници Фаза 1

Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis

Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

Trial status: Authorised

Начало: 22.04.2026 Възраст: от 18 г.

France, Italy Genentech Inc. 2025-522904-26-00

1 … 4 5 6 7 8 … 222